The Simplified Investor

A Blog about Stocks and Market Forces

Archive for the ‘Pharmaceuticals’ Category

23 Votes Short? Time to Invest in the Almighty Apple

I know what you’re thinking - why invest in Apple when its stock price fell 18% today? But think literally about apples, which you’ll find in any outdoor fruit stand on the streets of New York. Today, our sadly ineffective government failed to pass its so-called “bailout” plan. The meaning is clear - our economy is going to get a whole lot worse before it gets better. People are going to be out of their jobs (some estimate as many as 6 million Americans will soon be unemployed) - so saddle up the push cart, hit the pavement, and get ready to earn a living one apple at a time.

September 29, 2008 Vote, U.S. House of Representatives

September 29, 2008 Vote, U.S. House of Representatives

What happened today was historic, and the market knew it. $1.2 trillion was erased from the market value of American stocks as frightened investors fled for the safety of gold and government Treasury bonds. The Dow Jones Industrial Average fell 777 points, the largest one day decline since the index was first published in 1896. The S&P 500 fell almost 9%, a drop not seen in two decades. Meanwhile, Wachovia Bank was bought by Citigroup for $1 a share, making it just the latest financial institution to surrender in a fear-driven downward spiral that has crushed venerable institutions like Lehman Brothers, Merrill Lynch, and Washington Mutual in recent weeks.

(more…)

More on this topic (What's this?)
Apple Investors Step Away from the Distortion Field
23 Votes Short? Time to Invest in the Almighty Apple
Read more on Apple at Wikinvest

FDA Strikes Another Blow to Amgen’s Anemic Drug Sales

Amgen (NYSE:AMGN) made its reputation as one of the premier firms in the biotechnology industry with its blockbuster anemia drugs, Aranesp and Epogen. Worldwide sales of anemia drugs made up around half of Amgen’s $14.8B revenue in 2007 and an even larger percentage of its profit - Epogen, its original bestselling medicine, brought in revenues of $2.5B, while Aranesp sales hit $3.6B. But these impressive totals obscure falling demand for the drugs - in the the second quarter of 2008, for example, sales in the United States plunged 26 percent.
(more…)

More on this topic (What's this?)
FDA Strikes Another Blow to Amgen’s Anemic Drug Sales
Amgen’s Stock on a Roll
Read more on Amgen at Wikinvest

You are currently browsing the archives for the Pharmaceuticals category.


Market Blogs
Powered By Ringsurf

Technorati Profile